Hepatitis B and hepatitis C prevalence among people living with HIV/AIDS in China: a systematic review and Meta-analysis
- PDF / 1,770,290 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 108 Downloads / 193 Views
REVIEW
Open Access
Hepatitis B and hepatitis C prevalence among people living with HIV/AIDS in China: a systematic review and Meta-analysis Songxia Yu1, Chengbo Yu2, Jian Li3, Shiming Liu3, Haowen Wang3 and Min Deng3*
Abstract Background: There has been little published data on estimates of HBV and/or HCV coinfection in HIV-positive patients in China or an understanding of how this coinfection varies with different factors. Therefore, this study aimed to determine, through a systematic review and meta-analysis, the prevalence of HBV and/or HCV in HIVpositive patients in China and explore variations in prevalence. Methods: The Medicine, Web of Science, Chinese Web of Knowledge, and Wanfang databases were searched using a search strategy combining key words and related disease-specific subject terms to identify relevant cohort or cross-sectional studies published up to April 2019. Included articles were assessed for quality. Pooled prevalence and 95% confidence intervals (CIs) were calculated according to study region and other specific characteristics. Results: Our searches identified 7843 records, but only 66 studies were included in our meta-analysis. The pooled HBsAg prevalence in HIV-positive patients was 13.7% (95% CI 12.3–15.3%), with variations found in terms of age and geographic region. The meta-HCV prevalence was 24.7% (95% CI 19.3–30.5%), which varied over the study period and age. The pooled HBV-HCV coinfection prevalence was 3.5% (95% CI 2.4–4.8%), with variations found in terms of age and geographic region. Conclusion: Given the high burden of HBV and HCV coinfections in HIV-positive patients, the incorporation of comprehensive screening, treatment, prevention, and vaccination programs into general HIV management in China is imperative. Keywords: Hepatitis B, Hepatitis C, HIV, Meta-analysis, Coinfection
Background The launch and advancement of antiretroviral therapy (ART) has significantly decreased the mortality rates among people living with HIV/AIDS (PLWHA) worldwide and transformed HIV/AIDS from a lethal disease to a chronic manageable condition [1]. Although China * Correspondence: [email protected] 3 Department of Interventional medicine, Zhejiang Provincial People’s Hospital, Hangzhou 310003, Zhejiang, China Full list of author information is available at the end of the article
has a low HIV/AIDS epidemic in the general population, the number of PLWHA continues to increase. The Chinese Center for Disease Control and Prevention (CDC) estimated that there were approximately 500,000 people who were infected with HIV by the end of 2014 [2], and at the end of June 2017, this number had changed to 660,000, including 41.7% of whom were already AIDS patients [3]. China is also a country with a heavy disease burden for hepatitis B (HBV) and hepatitis C (HCV). Globally, there were an estimated 2 billion
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any
Data Loading...
